Antiplatelet Dosing for Acute MI in Warfarin Patients
For a patient on warfarin who develops acute myocardial infarction, initiate aspirin 162-325 mg loading dose (chewed if possible) followed by 75-100 mg daily maintenance, plus a P2Y12 inhibitor (preferably clopidogrel 600 mg loading, then 75 mg daily), with continuation of warfarin at moderate intensity (INR 2.0-3.0) for triple therapy. 1
Initial Antiplatelet Loading
Start aspirin immediately upon presentation:
- Loading dose: 162-325 mg orally (non-enteric coated, chewed for faster absorption)
- Give this loading dose even if the patient is already on aspirin 1
- Maintenance: 75-100 mg daily (non-enteric coated) 1
Add a P2Y12 inhibitor based on management strategy:
For PCI Strategy (Primary or Urgent)
- Clopidogrel is preferred over prasugrel/ticagrelor when combined with warfarin due to lower bleeding risk 2
- Loading: 600 mg orally 1
- Maintenance: 75 mg daily 1
For Conservative/Medical Management
- Clopidogrel 300 mg loading if age ≤75 years
- Clopidogrel 75 mg loading if age >75 years
- Maintenance: 75 mg daily 1
Warfarin Management
Continue warfarin at moderate intensity (target INR 2.0-3.0) rather than discontinuing it 3. The FDA label specifically addresses post-MI patients on warfarin and supports combined therapy with low-dose aspirin (≤100 mg/day) for high-risk patients 3.
For high-risk features (large anterior MI, significant heart failure, visible intracardiac thrombus, or prior thromboembolic event), the combination of moderate-intensity warfarin plus low-dose aspirin is specifically recommended for at least 3 months 3.
Triple Therapy Duration
Minimize triple therapy duration to reduce bleeding risk:
- Use triple therapy (warfarin + aspirin + P2Y12 inhibitor) for the shortest period necessary
- Transition to dual therapy (warfarin + single antiplatelet agent, preferably clopidogrel) as soon as clinically appropriate 2
- Current evidence supports limiting triple therapy to the periprocedural period when possible 2
Critical Considerations
Bleeding risk is substantially elevated with triple therapy - approximately 4 times higher than aspirin alone 4. The WARIS II trial demonstrated major bleeding rates of 2.1-2.5 per 100 patient-years with warfarin-containing regimens versus 0.9 with aspirin alone 4.
Avoid prasugrel or ticagrelor when combining with warfarin - these more potent P2Y12 inhibitors significantly increase bleeding risk without proven benefit in this specific population 5, 2. Clopidogrel is the P2Y12 inhibitor of choice for triple therapy 2.
Do not use high-intensity warfarin (INR 3.0-4.0) when combining with antiplatelet therapy - moderate intensity (INR 2.0-3.0) provides adequate thrombotic protection with lower bleeding risk 3.
Common Pitfalls to Avoid
- Don't discontinue warfarin reflexively - patients on chronic warfarin have specific indications (AF, mechanical valves, prior thromboembolism) that persist despite acute MI
- Don't use full-dose aspirin (325 mg) for maintenance - low-dose (75-100 mg) is equally effective with less bleeding 1
- Don't extend triple therapy unnecessarily - bleeding risk accumulates over time without proportional ischemic benefit
- Don't combine warfarin with dual antiplatelet therapy using prasugrel or ticagrelor - this dramatically increases bleeding complications 2